155 related articles for article (PubMed ID: 8969375)
61. [Autotransfusion of red blood cell from cardiopulmonary bypass circuit blood after cardiac surgery].
Lenkutis T; Veikutiene A; Raliene L; Surkus J
Medicina (Kaunas); 2002; 38 Suppl 2():213-6. PubMed ID: 12560664
[TBL] [Abstract][Full Text] [Related]
62. Biocompatibility of heparin-coated cardiopulmonary bypass circuits in coronary patients with left ventricular dysfunction is superior to PMEA-coated circuits.
Kutay V; Noyan T; Ozcan S; Melek Y; Ekim H; Yakut C
J Card Surg; 2006; 21(6):572-7. PubMed ID: 17073955
[TBL] [Abstract][Full Text] [Related]
63. Low dose systemic heparinization combined with heparin-coated extracorporeal circulation. Effects related to platelets.
Mirow N; Brinkmann T; Minami K; Tenderich G; Schulte-Eistrup S; Kleesiek K; Körfer R
J Cardiovasc Surg (Torino); 2001 Oct; 42(5):579-85. PubMed ID: 11562580
[TBL] [Abstract][Full Text] [Related]
64. Clinical performance and biocompatibility of novel hyaluronan-based heparin-bonded extracorporeal circuits.
Gunaydin S; Mccusker K; Vijay V
J Extra Corpor Technol; 2005 Sep; 37(3):290-5. PubMed ID: 16350383
[TBL] [Abstract][Full Text] [Related]
65. Decreased blood loss after cardiopulmonary bypass using heparin-coated circuit and 50% reduction of heparin dose.
Borowiec J; Thelin S; Bagge L; Hultman J; Hansson HE
Scand J Thorac Cardiovasc Surg; 1992; 26(3):177-85. PubMed ID: 1287831
[TBL] [Abstract][Full Text] [Related]
66. Aspirin does not increase allogeneic blood transfusion in reoperative coronary artery surgery.
Tuman KJ; McCarthy RJ; O'Connor CJ; McCarthy WE; Ivankovich AD
Anesth Analg; 1996 Dec; 83(6):1178-84. PubMed ID: 8942582
[TBL] [Abstract][Full Text] [Related]
67. Is 300 Seconds ACT Safe and Efficient during MiECC Procedures?
Bauer A; Hausmann H; Schaarschmidt J; Szlapka M; Scharpenberg M; Eberle T; Hasenkam JM
Thorac Cardiovasc Surg; 2019 Apr; 67(3):191-202. PubMed ID: 29290078
[TBL] [Abstract][Full Text] [Related]
68. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial.
Koster A; Dyke CM; Aldea G; Smedira NG; McCarthy HL; Aronson S; Hetzer R; Avery E; Spiess B; Lincoff AM
Ann Thorac Surg; 2007 Feb; 83(2):572-7. PubMed ID: 17257990
[TBL] [Abstract][Full Text] [Related]
69. Clinical Impact of Protamine Titration-Based Heparin Neutralization in Patients Undergoing Coronary Bypass Grafting Surgery.
Abuelkasem E; Mazzeffi MA; Henderson RA; Wipfli C; Monroe A; Strauss ER; Chow JH; Tanaka KA
J Cardiothorac Vasc Anesth; 2019 Aug; 33(8):2153-2160. PubMed ID: 30737123
[TBL] [Abstract][Full Text] [Related]
70. Low-dose heparin versus full-dose heparin with high-dose aprotinin during cardiopulmonary bypass. A preliminary report.
von Segesser LK; Garcia E; Turina MI
Tex Heart Inst J; 1993; 20(1):28-32. PubMed ID: 7685221
[TBL] [Abstract][Full Text] [Related]
71. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
[TBL] [Abstract][Full Text] [Related]
72. Challenges with heparin-based anticoagulation during cardiopulmonary bypass in children: Impact of low antithrombin activity.
Manlhiot C; Gruenwald CE; Holtby HM; Brandão LR; Chan AK; Van Arsdell GS; McCrindle BW
J Thorac Cardiovasc Surg; 2016 Feb; 151(2):444-50. PubMed ID: 26553458
[TBL] [Abstract][Full Text] [Related]
73. A comparison of activated coagulation time-based techniques for anticoagulation during cardiac surgery with cardiopulmonary bypass.
Slight RD; Buell R; Nzewi OC; McClelland DB; Mankad PS
J Cardiothorac Vasc Anesth; 2008 Feb; 22(1):47-52. PubMed ID: 18249330
[TBL] [Abstract][Full Text] [Related]
74. Cell salvage during coronary artery bypass surgery and allogenic blood exposure.
Al-Mandhari S; Maddali MM; Al-Bahrani MJ
Asian Cardiovasc Thorac Ann; 2015 Oct; 23(8):913-6. PubMed ID: 26113735
[TBL] [Abstract][Full Text] [Related]
75. Heparin-coated bypass circuits (Carmeda) suppress the release of tissue plasminogen activator during normothermic coronary artery bypass graft surgery.
Spiess BD; Vocelka C; Cochran RP; Soltow L; Chandler WL
J Cardiothorac Vasc Anesth; 1998 Jun; 12(3):299-304. PubMed ID: 9636912
[TBL] [Abstract][Full Text] [Related]
76. The influence of acute preoperative plasmapheresis on coagulation tests, fibrinolysis, blood loss and transfusion requirements in cardiac surgery.
Menges T; Welters I; Wagner RM; Boldt J; Dapper F; Hempelmann G
Eur J Cardiothorac Surg; 1997 Mar; 11(3):557-63. PubMed ID: 9105824
[TBL] [Abstract][Full Text] [Related]
77. Haemostasis at low heparin dosage during cardiopulmonary bypass with heparin-coated circuits in pigs.
Bagge L; Borowiec JW; Thelin S; Hultman J
Scand Cardiovasc J; 1997; 31(5):275-81. PubMed ID: 9406294
[TBL] [Abstract][Full Text] [Related]
78. Low heparinization with heparin-bonded bypass circuits: is it a safe strategy?
Bannan S; Danby A; Cowan D; Ashraf S; Martin PG
Ann Thorac Surg; 1997 Mar; 63(3):663-8. PubMed ID: 9066381
[TBL] [Abstract][Full Text] [Related]
79. Tranexamic acid is effective in decreasing postoperative bleeding and transfusions in primary coronary artery bypass operations: a double-blind, randomized, placebo-controlled trial.
Brown RS; Thwaites BK; Mongan PD
Anesth Analg; 1997 Nov; 85(5):963-70. PubMed ID: 9356085
[TBL] [Abstract][Full Text] [Related]
80. Thrombin generation during cardiopulmonary bypass using heparin-coated or standard circuits.
Ernofsson M; Thelin S; Siegbahn A
Scand J Thorac Cardiovasc Surg; 1995; 29(4):157-65. PubMed ID: 8789468
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
